Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Shree Allada, Richa Parikh, Ajay Nooka, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2025-4078

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Ajay Nooka, Nishi Shah, Lawrence Boise, Sagar Lonial

Blood (2025) 146 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2025-2823

Published: 2025

Journal Articles

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Om Raval, Lilly Gu, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2025-2812

Published: 2025

Journal Articles

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2025-2811

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Impact of extrinsic heme on adoptive T cell therapy

Dejah Blake, Pulkit Gupta, Remya Nair, Ruby Freeman, Heather Lin, Sagar Lonial, Benjamin Barwick, Ajay Nooka, Jean Koff, Sarwish Rafiq, Mala Shanmugam

Blood (2025) 146 (Supplement 1): 7628.

https://doi.org/10.1182/blood-2025-7628

Published: 2025

Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2025-5843

Published: 2025

Journal Articles

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Kiran Lakhani, Yu Zhang, Jonathan Keats, Vikas Gupta, Sagar Lonial, Nisha Joseph, Ajay Nooka, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2025-2251

Published: 2025

Journal Articles

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Blood (2025) 146 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2025-2237

Published: 2025

Journal Articles

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Dominique Mosley, Richa Parikh, Sara Scott, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2025-3968

Published: 2025

Journal Articles

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Nisha Joseph, Richa Parikh, Shree Allada, Vikas Gupta, Craig Hofmeister, Nishi Shah, Jonathan Kaufman, Sagar Lonial, Ajay Nooka

Blood (2025) 146 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2025-2301

Published: 2025

Journal Articles

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay Nooka, Salomon Manier, Shinsuke Iida, Sophie Hello, Devender Dhanda, Prachi Ghodke, Martina Raggi, Roland Marion Gallois, Jaclyn Davis, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2297.

https://doi.org/10.1182/blood-2025-2297

Published: 2025

Journal Articles

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Blood (2025) 146 (Supplement 1): 4014.

https://doi.org/10.1182/blood-2025-4014

Published: 2025

Journal Articles

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Blood (2025) 146 (Supplement 1): 269.

https://doi.org/10.1182/blood-2025-269

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies

Chadi Nabhan, Jeremy Abramson, Tyler Fraum, Ajay Nooka, Gary Schiller, David Schuster, Michael Thirman, Kayla Haines, Erin Shonkwiler, Mohammad Jahanzeb

Blood (2025) 146 (Supplement 1): 4359.

https://doi.org/10.1182/blood-2025-4359

Published: 2025

Journal Articles

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph, Maria Gavriatopoulou, Lilly Gu, Craig Hofmeister, Vikas Gupta, Evangelos Terpos, Ajay Nooka, Sagar Lonial, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 407.

https://doi.org/10.1182/blood-2025-407

Published: 2025

Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139332

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Impact of extrinsic heme on adoptive T cell therapy

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only